Methyl 2-[3-(5-bromo-1,3-dioxoisoindol-2-yl)propylcarbamoylamino]benzoate
C20H18BrN3O5 — CID 108889777
Data last refreshed: (MolForge compound catalog, from PubChem)
About Methyl 2-[3-(5-bromo-1,3-dioxoisoindol-2-yl)propylcarbamoylamino]benzoate
Methyl 2-[3-(5-bromo-1,3-dioxoisoindol-2-yl)propylcarbamoylamino]benzoate (PubChem CID 108889777) has the molecular formula C20H18BrN3O5 and a molecular weight of 460.28 g/mol. Its IUPAC name is methyl 2-[3-(5-bromo-1,3-dioxoisoindol-2-yl)propylcarbamoylamino]benzoate.
Molecular Properties
| Compound Name | Methyl 2-[3-(5-bromo-1,3-dioxoisoindol-2-yl)propylcarbamoylamino]benzoate |
|---|---|
| PubChem CID | 108889777 |
| Molecular Formula | C20H18BrN3O5 |
| Molecular Weight | 460.28 g/mol |
| Exact Mass | 459.04 |
| IUPAC Name | methyl 2-[3-(5-bromo-1,3-dioxoisoindol-2-yl)propylcarbamoylamino]benzoate |
| SMILES | COC(=O)c1ccccc1NC(=O)NCCCN1C(=O)c2ccc(Br)cc2C1=O |
| InChI | InChI=1S/C20H18BrN3O5/c1-29-19(27)14-5-2-3-6-16(14)23-20(28)22-9-4-10-24-17(25)13-8-7-12(21)11-15(13)18(24)26/h2-3,5-8,11H,4,9-10H2,1H3,(H2,22,23,28) |
| InChIKey | RETQKWXPDHZQDN-UHFFFAOYSA-N |
| XLogP | 3.04 |
| TPSA | 104.81 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 460.28 |
| LogP ≤ 5 | 3.04 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 5 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'}, {'alert_name': 'phthalimide', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 108889777 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.